Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland
Sponsor: Burzynski Research Institute
Terminated
Slow enrollment
Other terminated trials from Burzynski Research Institute
This PHASE2 trial investigates Stage IV Adrenocortical Carcinoma and is currently terminated or withdrawn. Burzynski Research Institute leads this study, which shows 9 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Feb 2017 — Oct 2017 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Aug 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Burzynski Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .